Skip to main content
Contact Us
Subscribe
E-Edition
47°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amylyx Pharmaceuticals, Inc.
< Previous
1
2
3
Next >
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
December 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
November 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
October 17, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
October 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
August 12, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
August 05, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
August 02, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
July 10, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
July 09, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results
May 09, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference
May 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
May 02, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
April 10, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
April 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
April 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
March 14, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
March 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 23, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
February 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
February 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
February 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
December 22, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
December 04, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2023
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Tickers
AMLX
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.